Application of active lymphocyte immunotherapy in patients with recurrent implantation failure / 中国医师进修杂志

ABSTRACT

Objective:To analyze the effect of active lymphocyte immunotherapy (LIT) in patients with recurrent implantation failure (RIF), as well as its influence on serum galectin-3, galectin-1, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in cervical secretions.Methods:From January 2018 to March 2019, 144 patients with in-vitro fertilization and embryo transfer (IVF-ET) admitted to the First People′s Hospital of Tianmen were enrolled. Among them, there were 66 patients with RIF (RIF group) and 78 cases without RIF (non-RIF group). First, the differences of serum galectin-3, galectin-1, TNF-α and IL-6 in cervical secretions were compared between the two groups. Subsequently, the patients with RIF were treated with LIT, and the therapeutic effects were observed. The differences of the above indicators before and after treatment were compared.Results:The levels of serum galectin-1, galectin-3 and cervical secretion IL-6 in patients with RIF were lower than those in non-RIF patients [ovulation day (35.94 ± 3.91) μg/L vs. (39.26 ± 3.75) μg/L, (53.10 ± 5.91) μg/L vs. (57.68 ± 6.87) μg/L, (73.13 ± 16.69) μg/L vs. (90.98 ± 16.25) μg/L; after ovulation for 6 d (43.13 ± 4.53) μg/L vs. (48.95 ± 6.23) μg/L, (68.61 ± 7.70) μg/L vs. (72.25 ± 7.94) μg/L, (81.11 ± 16.02) μg/L vs. (91.21 ± 18.13) μg/L], the level of TNF-α in cervical secretion was higher than that in non-RIF patients [ovulation day (13.33 ± 1.76) μg/L vs. (10.20 ± 1.74) μg/L; after ovulation for 6 d (12.17 ± 1.64) μg/L vs. (9.36 ± 1.84) μg/L], and the differences were statistically significant ( P<0.05). After LIT treatment, the embryo implantation rate was 25.45% (42/165), the clinical pregnancy rate was 48.48% (32/66), and the abortion rate was 9.38% (3/32). After treatment, the serum galectin-1, galectin-3, cervical secretion IL-6 levels were higher than those before treatment, cervical secretions TNF-α levels were lower than before treatment, and the differences were statistically significant ( P<0.05). Conclusions:The levels of serum galectin-1, galectin-3, cervical secretions TNF-α, IL-6 in patients with RIF are different from those in non-RIF patients. LIT treatment can reduce the difference of these indicators and has certain treatment effect for patients with RIF.